home / stock / cprx / cprx news


CPRX News and Press, Catalyst Pharmaceuticals Inc. From 02/17/21

Stock Information

Company Name: Catalyst Pharmaceuticals Inc.
Stock Symbol: CPRX
Market: NASDAQ
Website: catalystpharma.com

Menu

CPRX CPRX Quote CPRX Short CPRX News CPRX Articles CPRX Message Board
Get CPRX Alerts

News, Short Squeeze, Breakout and More Instantly...

CPRX - Penny Stocks To Buy According To Analysts & Price Forecasts Up To 439%

Analysts Rate These Penny Stocks A Buy Right Now Finding the best penny stocks to buy right now can be a tall order. Not only are you dealing with noise in the market, but you’re also dealing with noise online. Set up any penny stock screener, and you’ll know what I&#x...

CPRX - 3 Biotech Stocks on the Robinhood 100 to AVOID

The Robinhood app is popular among millennial investors. And as the Covid-19 pandemic focused attention on the biotech industry last year, many young investors rushed to bet on the sector. Though market hype has lately helped usher many biotech stocks onto the Robinhood 100 list (of most popu...

CPRX - Catalyst Pharma sees FY20 revenue as high as $118M, provides update on product expansion

Catalyst Pharmaceuticals (CPRX) estimates Firdapse annual net revenues for 2020 at ~$118M, an increase of ~16% from 2019. The Board of Directors recently approved an expansion in the company's strategic focus to include acquiring or in-licensing validated technology platforms and earlier stag...

CPRX - Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update

Company to Expand R&D Focus for Pipeline Growth to include Earlier Stage Programs and Validated Technology Platforms Firdapse® 2020 Net Revenues Estimate of approximately $118 Million; about 16% Increase From 2019 Ended 2020 with Estimated $140 Million i...

CPRX - Catalyst Pharmaceuticals: Attractive Valuation Has Priced In Risks

Catalyst Pharma is a commercial-stage small biotech with a highly profitable orphan drug Firdapse for adult LEMS patients in the US market. Catalyst Pharma is trading at PE ratio of 5 and price-to-sales ratio of 2.96. The company exited Q3 with $127M in cash and no debt. The low v...

CPRX - A+ Top Quant Rated Healthcare Stocks For Value, Growth, And Profitability

Three referenced quant rating categories (value, growth, and profitability) are significant considerations in selecting healthcare investments. The data underlying the value, growth, and profitability tabs runs a significant gamut of the information properly considered in performing d...

CPRX - Hot Penny Stocks To Buy According To 3 Analysts With 58%-211% Targets

Penny Stocks to Watch With Strong Momentum in December With COVID cases on the rise and a new president in the U.S., speculative traders have found a lot of luck with penny stocks . While not all penny stocks are worth watching, if investors do the research, they can find the ones t...

CPRX - Seeking Alpha Catalyst Watch

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. A ho...

CPRX - Catalyst Pharmaceuticals Inc (CPRX) Q3 2020 Earnings Call Transcript

Image source: The Motley Fool. Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Q3 2020 Earnings Call Nov 10, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Catalyst Pharmaceuticals Inc (CPRX) Q3 2020 Earnings Call Tran...

CPRX - Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2020 Results - Earnings Call Transcript

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2020 Earnings Conference Call November 10, 2020 8:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman & Chief Executive Officer Steven Miller - Chief Operating Officer & Chief Scientific Officer Jeff...

Previous 10 Next 10